Enhanced transdermal delivery of loratadine from the EVA matrix

Optimized vinpocetine-loaded vitamin E D-α-tocopherol polyethylene glycol 1000 succinate-alpha lipoic acid micelles as a potential transdermal drug delivery system: in vitro and ex vivo studies

“…46,47 The penetration enhancer may also reduce the capacity of drug binding to the skin, thereby improving drug transport. 43,48 A similar permeation-enhancing effect of citral was reported by Ali et al, who developed glibenclamide transdermal matrix system. 49 The same finding was found with X 3 ; as the percentage of PG (X 3 , plasticizer) increased, the percent of VNP permeated via the rat skin increased.…”

“…42 So, the incorporation of the appropriate plasticizer concentration is important to improve the elasticity, increase toughness, and reduce the brittleness of the prepared film. 43 To obtain a tough but flexible film, the current study aimed to investigate the effect of PG at different levels from 1% to 5%. The obtained results…”

Loratadine bioavailability via buccal transferosomal gel: formulation, statistical optimization,in vitro/in vivocharacterization, and pharmacokinetics in human volunteers

“…Attempts to mitigate LTD poor oral bioavailability have relied on two strategies; (i) improving drug’s limited solubility in gastrointestinal fluid through β-cyclodextrin complexation (Szabados-Nacsa et al, 2011 ) and self-microemulsifying drug delivery systems (Li et al, 2015 ), and (ii) bypassing hepatic first-pass metabolism through non-oral administration (Cho et al, 2009 ; Song & Shin, 2009 ; Singh et al, 2013 ; Chakraborty et al, 2014 ; Kumria et al, 2014 ). Published reports (Chakraborty et al, 2014 ) suggested the buccal administration as an alternative route for systemic delivery of LTD.…”